1
|
Meng W, Brigance R, Mignone J, Negash L, Zhao G, Ahmad S, Wang W, Moore F, Ye XY, Sun JH, Mathur A, Li YX, Azzara A, Ma Z, Chu CH, Cullen MJ, Rooney S, Harvey S, Kopcho L, Abell L, O'Malley K, Keim W, Dierks EA, Chang S, Foster KA, Harden D, Dabros M, Goti V, De Oliveira C, Krishna G, Pelleymounter MA, Whaley J, Robl JA, Cheng D, Devasthale P. Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders. J Med Chem 2023; 66:13135-13147. [PMID: 37724542 DOI: 10.1021/acs.jmedchem.3c01147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
A series of dihydropyridinone (DHP) compounds was prepared and evaluated for MGAT2 activity. The efforts led to the identification of novel tetrazolones with potent MGAT2 inhibitory activity and favorable in vitro profiles. Further tests of select analogues in mouse models revealed significant reduction in food intake and body weight. Subsequent studies in MGAT2 knockout mice with the lead candidate 12 (BMS-986172) showed on-target- and mechanism-based pharmacology. Moreover, its favorable pharmacokinetic (PK) profile and the lack of species variability in the glucuronidation potential resulted in a greater confidence level in the projection of a low dose for achieving targeted efficacious exposures in humans. Consistent with these projections, PK data from a phase 1 trial confirmed that targeted efficacious exposures could be achieved at a low dose in humans, which supported compound 12 as our second and potentially superior development candidate for the treatment of various metabolic disorders.
Collapse
|
2
|
Kempson J, Hou X, Sun JH, Wong M, Pawluczyk J, Li J, Krishnananthan S, Simmons EM, Hsiao Y, Li YX, Sun D, Wu DR, Meng W, Ahmad S, Negash L, Brigance R, Turdi H, Hangeland JJ, Lawrence RM, Devasthale P, Robl JA, Mathur A. Synthesis Optimization, Scale-Up, and Catalyst Screening Efforts toward the MGAT2 Clinical Candidate, BMS-963272. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.2c00036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- James Kempson
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Xiaoping Hou
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Jung-Hui Sun
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Michael Wong
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Joseph Pawluczyk
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Jianqing Li
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | | | - Eric M. Simmons
- Chemical Development, Bristol-Myers Squibb, New Brunswick, New Jersey 08903, United States
| | - Yi Hsiao
- Chemical Development, Bristol-Myers Squibb, New Brunswick, New Jersey 08903, United States
| | - Yi-Xin Li
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Dawn Sun
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Dauh-Rurng Wu
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Wei Meng
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Saleem Ahmad
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Lidet Negash
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Robert Brigance
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Huji Turdi
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Jon J. Hangeland
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - R. Michael Lawrence
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Pratik Devasthale
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Jeffrey A. Robl
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| | - Arvind Mathur
- Discovery Chemistry, Bristol-Myers Squibb, Princeton, New Jersey 08540, United States
| |
Collapse
|
3
|
Meng W, Pi Z, Brigance R, Rossi KA, Schumacher WA, Bostwick JS, Gargalovic PS, Onorato JM, Luk CE, Generaux CN, Wang T, Wexler RR, Finlay HJ. Identification of a Hydroxypyrimidinone Compound ( 21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure. J Med Chem 2021; 64:18102-18113. [PMID: 34855405 DOI: 10.1021/acs.jmedchem.1c01504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
This paper describes our continued efforts in the area of small-molecule apelin receptor agonists. Recently disclosed compound 2 showed an acceptable metabolic stability but demonstrated monodemethylation of the dimethoxyphenyl group to generate atropisomer metabolites in vitro. In this article, we extended the structure-activity relationship at the C2 position that led to the identification of potent pyrazole analogues with excellent metabolic stability. Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. Compound 21 displayed excellent pharmacokinetic profiles in rat, monkey, and dog models and robust pharmacodynamic efficacy in the rodent heart failure model. Compound 21 also showed an acceptable safety profile in preclinical toxicology studies and was selected as a backup development candidate for the program.
Collapse
Affiliation(s)
- Wei Meng
- Departments of Discovery Chemistry, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Zulan Pi
- Departments of Discovery Chemistry, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Robert Brigance
- Departments of Discovery Chemistry, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Karen A Rossi
- Computer-Assisted Drug Design, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - William A Schumacher
- Cardiovascular Drug Discovery Biology, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Jeffrey S Bostwick
- Cardiovascular Drug Discovery Biology, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Peter S Gargalovic
- Cardiovascular Drug Discovery Biology, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Joelle M Onorato
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Chiuwa E Luk
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Claudia N Generaux
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Tao Wang
- Leads Discovery and Optimization, Research and Development, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Ruth R Wexler
- Departments of Discovery Chemistry, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| | - Heather J Finlay
- Departments of Discovery Chemistry, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States
| |
Collapse
|
4
|
Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P. Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. J Med Chem 2021; 64:14773-14792. [PMID: 34613725 DOI: 10.1021/acs.jmedchem.1c01356] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
MGAT2 inhibition is a potential therapeutic approach for the treatment of metabolic disorders. High-throughput screening of the BMS internal compound collection identified the aryl dihydropyridinone compound 1 (hMGAT2 IC50 = 175 nM) as a hit. Compound 1 had moderate potency against human MGAT2, was inactive vs mouse MGAT2 and had poor microsomal metabolic stability. A novel chemistry route was developed to synthesize aryl dihydropyridinone analogs to explore structure-activity relationship around this hit, leading to the discovery of potent and selective MGAT2 inhibitors 21f, 21s, and 28e that are stable to liver microsomal metabolism. After triaging out 21f due to its inferior in vivo potency, pharmacokinetics, and structure-based liabilities and tetrazole 28e due to its inferior channel liability profile, 21s (BMS-963272) was selected as the clinical candidate following demonstration of on-target weight loss efficacy in the diet-induced obese mouse model and an acceptable safety and tolerability profile in multiple preclinical species.
Collapse
|
5
|
Behnia K, Cornelius G, Wang J, Shipkova P, Johnghar S, Washburn W, Brigance R, Stetsko P, Henwood A, Wojciechowski JP, Marathe P, Rodrigues AD, Humphreys WG. Estimation of the Extent ofin VivoFormation of a Mutagenic Aromatic Amine from a Potent Thyromimetic Compound: Correlation ofin Vitroandin VivoFindings. Chem Res Toxicol 2011; 24:905-12. [DOI: 10.1021/tx200087q] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Mobilio D, Humber LG, Katz AH, Demerson CA, Hughes P, Brigance R, Conway K, Shah U, Williams G, Labbadia F. Structure-activity relationships among analogues of pemedolac, cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indo le-1-a cetic acid, a potent analgesic agent. J Med Chem 1988; 31:2211-7. [PMID: 3263504 DOI: 10.1021/jm00119a024] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The syntheses of analogues of pemedolac (cis-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyrano[3,4-b]indol e-1-acetic acid), a potent analgesic, are described. They were tested for analgesic and antiinflammatory effects in vivo and for inhibition of prostaglandin production in vitro. Analysis of structure-activity relationships shows that analgesic activity in this series is associated with 1S-cis stereochemistry, the presence of a pi-system (allyl or benzyl) at position 4, and a log P value greater than 4.0.
Collapse
Affiliation(s)
- D Mobilio
- Ayerst Laboratories Research Inc., Princeton, New Jersey 08543-8000
| | | | | | | | | | | | | | | | | | | |
Collapse
|